Drug Profile
Research programme: anti-herpes zoster therapeutic antibodies - XBiotech
Latest Information Update: 15 Sep 2022
Price :
$50
*
At a glance
- Originator XBiotech
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Herpes zoster